The Pharmacy Times® Atopic Dermatitis Resource Center is a comprehensive resource for clinical news and expert insights on treatments for atopic dermatitis.
March 22nd 2023
The primary outcome of the study includes an IGA score of 0 or 1, which indicated clear or almost clear skin, respectively, with a reduction, from baseline to week 16.
Lebrikuzumab Found to Maintain Durable Skin Clearance When Dosed Every 4 Weeks in Atopic DermatitisSeptember 14th 2022
ADvocate 1 and ADvocate 2 are 52-week randomized, double-blind phase 3 studies designed to evaluate lebrikizumab as monotherapy in adult and adolescent patients with moderate to severe AD.
Clinical Overview: Lebrikizumab for Atopic DermatitisAugust 11th 2022
Lebrikizumab is a novel monoclonal antibody that binds with high affinity to the IL-13 protein to prevent the interaction between IL-13Rα1 and IL-4Rα, which blocks downstream signal activation along the IL-13 pathway.
FDA Approves Dupilumab for Children 6 Months to 5 Years of Age With Atopic DermatitisJune 8th 2022
Approval in this patient population makes dupilumab the first and only biologic medicine approved for the treatment of moderate-to-severe atopic dermatitis from infancy through adulthood.
FDA Accepts Dupixent for Priority Review in Young Children With Atopic DermatitisFebruary 15th 2022
If approved, Dipilumab will be the first biologic medicine available in the United States to treat uncontrolled moderate-to-severe AD for patients aged 6 months to 5 years.
FDA Approvals of Upadacitinib, Abrocitinib for Refractory Atopic Dermatitis Come With Boxed Warnings, Restrictive LabellingJanuary 25th 2022
The 2 drugs are the first small molecule JAK-1 inhibitors to be approved in the United States as treatment options for patients who are not responding to other therapies.